Biosimilar Contract Manufacturing Market to Grow with a CAGR of 16.59% through 2030

Increasing chronic disease is expected to drive the growth of global biosimilar contract manufacturing in the forecast period, 2026-2030.

According to TechSci Research report, “Biosimilar Contract Manufacturing Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2030”, the Global Biosimilar Contract Manufacturing Market stood at USD 9.37 billion in 2024 and is anticipated to grow with a CAGR of 16.59% in the forecast period through 2030. This can be ascribed to the increasing prevalence of diabetes, various type of cancers, neurological disorders, and availability of biosimilar at lower costs over branded products across the globe. Additionally, increasing focus on contract developments in countries like China, India and increasing prevalence of auto immune diseases are expected to create lucrative opportunities for the market growth in coming years. Besides, increasing research and development activities in biotechnology industry is further expected to support the market growth. Similarly, growing demand for low cost and highly efficient therapeutics is also expected to create significant growth during the forecasted period. Also, the growing demand for manufacturing along with the growing production of microbial products such as cytokines, hormones, enzymes, and MABs will drive the growth of the market during the forecasted period.

However, high cost of biosimilar drugs and subsequent therapies for the treatment of chronic diseases tend to slow down the growth of global biosimilar contract manufacturing market in the forecast period. Similarly, high risks and complications associated with biosimilar drugs and lack of skilled professionals may hamper the biosimilar contract manufacturing market growth during the forecast period. Also, poor reimbursement scenario and lack of insurance coverage for cancer treatment in emerging countries can further restrict the growth of global biosimilar contract manufacturing market.

Browse over XX market data Figures spread through XX Pages and an in-depth TOC on "Biosimilar Contract Manufacturing Market"

The Global Biosimilar Contract Manufacturing market is segmented into product, technology, application, regional distribution and company.

Based on Application, the Oncology segment is experiencing the fastest growth in the global Biosimilar Contract Manufacturing market. This surge is primarily driven by the escalating global incidence of cancer and the consequent demand for cost-effective therapeutic alternatives. Biosimilars, which are highly like their reference biologic drugs, offer a more affordable option for cancer treatment without compromising efficacy or safety. The expiration of patents for several blockbuster oncology biologics, such as trastuzumab, bevacizumab, and rituximab, has opened the market for biosimilar versions, thereby enhancing accessibility and affordability of cancer therapies. The high-cost burden of cancer care on healthcare systems worldwide has created strong incentives for the adoption of biosimilars. Hospitals and oncology clinics are increasingly integrating these alternatives into treatment protocols to manage costs while maintaining treatment standards. This trend is further supported by real-world studies affirming the clinical equivalence of biosimilars to their reference products, bolstering confidence among healthcare providers and patients alike.

Based on the Region, Asia Pacific region emerges as the fastest growth in the global biosimilar contract manufacturing market due to a confluence of supportive regulatory reforms, increasing healthcare needs, and robust investments in biopharmaceutical infrastructure. Countries such as India, China, and South Korea have actively promoted biotechnology sectors through national initiatives and funding programs that encourage local manufacturing, technology transfer, and innovation. For example, India’s focus on strengthening its pharmaceutical ecosystem under programs like “Make in India” has led to the rapid expansion of biologics and biosimilar manufacturing capabilities. China, on the other hand, has streamlined its drug approval processes and encouraged public-private collaborations to boost local production and reduce reliance on imported biologics.

Major companies operating in global biosimilar contract manufacturing market are:

• Catalent, Inc.
• Boehringer Ingelheim GmbH
• Alcami Corporation, Inc.
• Almac Group
• Lonza Group AG
• Biocon Limited
• Avid Bioservice, Inc.
• Rentschler Biopharma SE
• Fujifilm Kyowa Kirin Biologics Co., Ltd.
• WuXi Biologics, Inc.

Download Free Sample Report

Customers can also request for 10% free customization on this report.

“The North American region was expected to dominate in the global biosimilar contract manufacturing market due to the increasingly developed biosimilar contract organizations in the developing countries. Furthermore, increasing developed healthcare infrastructure and increasing product introductions are further contributing to the demand for biosimilar contract manufacturing. Similarly, growing approvals of biosimilar drugs in recent years and growing demand for less expensive therapeutic products, and the high prevalence of chronic diseases are expected to drive market growth over the years. Additionally, the increasing the incidence of non-communicable diseases such as diabetes and autoimmune disorders is fueling the demand for cost-effective treatments and will drive market growth over the years. Besides, increasing demand for less expensive therapeutic products and increasing prevalence of chronic diseases like cancers in the region are further expected to create lucrative opportunities for the market growth”, said Mr. Karan Chechi, Research Director of TechSci Research, a research based global management consulting firm.

“Biosimilar Contract Manufacturing Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product (Recombinant Non-glycosylated Proteins, Recombinant Glycosylated Proteins), By Technology (Mammalian, Non-Mammalian), By Application (Oncology, Blood Disorders, Growth Hormonal Deficiency, Chronic & Autoimmune Disorders, Rheumatoid Arthritis, Others), By Region and Competition, 2020-2030F”, has evaluated the future growth potential of global biosimilar contract manufacturing market and provides statistics & information on market size, structure, and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges, and opportunities in global biosimilar contract manufacturing market.